证券日报网讯 9月2日晚间，亨迪药业发布公告称，公司第二届董事会第十五次会议审议通过了《关于 变更公司注册资本、修订公司章程并办理工商变更登记的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 9月2日晚间，亨迪药业发布公告称，公司将于2025年9月18日召开2025年第二次临时股东 大会。本次股东大会将审议《关于变更公司注册资本、修订公司章程并办理工商变更登记的议案》《关 于修订公司部分治理制度的议案》。 （文章来源：证券日报） ...

证券日报网讯 9月2日晚间，亨迪药业发布公告称，公司第二届监事会第十四次会议审议通过了《关于 变更公司注册资本、修订公司章程并办理工商变更登记的议案》。 （文章来源：证券日报） ...

Core Points - The document outlines the rules for the shareholders' meeting of Hubei Hendi Pharmaceutical Co., Ltd, aiming to ensure compliance with laws and regulations while protecting shareholders' rights [1][2][3] Group 1: General Provisions - The rules are established to regulate the behavior of the company and ensure efficient decision-making at shareholders' meetings [1] - Shareholders' meetings can be classified into annual and temporary meetings, with annual meetings required to be held within six months after the end of the previous fiscal year [1][2] - The company must report to the China Securities Regulatory Commission and the stock exchange if it cannot convene a shareholders' meeting within the stipulated time [2] Group 2: Rights and Responsibilities - The shareholders' meeting is the company's authority body, exercising powers such as electing directors, approving profit distribution plans, and making decisions on capital changes [8][9] - The company must hire a lawyer to provide legal opinions on the legality of the meeting's procedures and results [2][3] Group 3: Transactions and Approvals - Certain transactions, such as external guarantees and significant asset purchases, require approval from the shareholders' meeting if they exceed specified thresholds [4][5][6] - The rules specify that transactions involving guarantees exceeding 30% of the company's audited total assets must be approved by the shareholders' meeting [4] Group 4: Shareholder Proposals and Notifications - Shareholders holding more than 1% of shares can propose temporary items for discussion at the shareholders' meeting, which must be notified within two days of receipt [35][36] - Notifications for annual meetings must be sent at least 20 days in advance, while temporary meetings require a 15-day notice [37][38] Group 5: Meeting Procedures - The shareholders' meeting must be held at the company's registered location, and provisions must be made for remote participation [42][43] - The meeting must be presided over by the chairman or a designated director, and all shareholders have the right to attend and vote [50][51] Group 6: Voting and Resolutions - Shareholders must express their votes as either in favor, against, or abstaining, and the results must be publicly disclosed [59][62] - The company must ensure that resolutions passed at the shareholders' meeting are implemented within two months [67]

募集资金管理制度 湖北亨迪药业股份有限公司 募集资金管理制度 第一章 总 则 第一条 为规范湖北亨迪药业股份有限公司（以下简称"公司"）募集资金 的管理和使用，最大限度地保障投资者的利益，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、《深圳证券交易所创业板上市公司规范运作指引》、 《深圳证券交易所创业板股票上市规则》（以下简称"《创业板上市规则》"）、 《首次公开发行股票并在创业板上市管理办法》、 《上市公司证券发行管理办法》、 《上市公司监管指引第 2 号--上市公司募集资金管理和使用的监管要求》、《创 业板信息披露业务备忘录第 1 号——超募资金及闲置募集资金使用》和《湖北亨 迪药业股份有限公司章程》(以下简称"《公司章程》")等法律、法规和规范性 文件的规定，结合公司实际情况，特制定《募集资金管理制度》(以下简称"本 制度")。 第二条 本制度适用于上市公司通过发行股票或者其他具有股权性质的证券， 向投资者募集并用于特定用途的资金监管，但不包括上市公司为实施股权激励计 划募集的资金监管。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较好的市场前景和盈利能力 ...

董事会议事规则 二〇二五年九月 第二章 董事会的组成机构 第四条 董事会由八名董事组成，其中独立董事三名，设职工代表董事一 名，设董事长一名，如有需要可同时设副董事长一名。 湖北亨迪药业股份有限公司 董事会议事规则 湖北亨迪药业股份有限公司 董事会议事规则 (2025 年 9 月) 第一章 总则 第一条 为了保护湖北亨迪药业股份有限公司（以下简称"公司"）和股 东的权益，规范本公司董事会的议事方式和决策程序，规范董事的行为，明晰董 事会的职责权限，促使董事和董事会有效地履行其职责，建立规范化的董事会组 织架构及运作程序，保障公司经营决策高效、有序地进行，依据《公司法》、《证 券法》、《上市公司治理准则》、《深圳证券交易所股票上市规则》和《上市公 司独立董事管理办法》等有关规定及本公司《公司章程》，制订本规则。 第二条 董事会是公司经营管理的决策机构，维护公司和全体股东的利益， 在《公司章程》和股东会的授权范围内，负责公司发展目标和重大经营活动的决 策，对股东会和全体股东负责。 第三条 董事会下设董事会办公室，由董事会秘书负责，处理董事会日常 事务。 第五条 董事会成员中应当有不低于总人数 1/3 的独立董事， ...

湖北亨迪药业股份有限公司 章程 二〇二五年九月 第一章 总则 第一条 为维护湖北亨迪药业股份有限公司（以下简称"公司"）、股 东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共 和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司 （以下简称公司）。 公司系由湖北百科亨迪药业有限公司依法整体变更，湖北百科亨迪药业有 限公司的债权债务由变更后的湖北亨迪药业股份有限公司承继，并由全体发起 人以发起方式设立；在荆门市市场监督管理局注册登记，并取得营业执照，统 一社会信用代码【91420800615406429F】。 第三条 公司于2021年11月16日经中华人民共和国证券监督管理委员会 （以下简称"中国证监会"）核准，首次向社会公众发行人民币普通股6,000万 股，于2021年12月22日在深圳证券交易所上市。 第四条 公司注册名称： 中文全称：湖北亨迪药业股份有限公司 英文全称：Hubei Biocause Heilen Pharmaceutical Co., Ltd 第五条 ...

Core Viewpoint - The document outlines the financial assistance management system of Hubei Hendi Pharmaceutical Co., Ltd, aiming to regulate external financial assistance, mitigate financial risks, and enhance information disclosure quality [1]. Group 1: General Principles - The system defines "external financial assistance" as the provision of funds or entrusted loans by the company and its subsidiaries, excluding certain conditions such as when lending is the main business or when the recipient is a majority-owned subsidiary [1]. - The company must protect shareholders' rights and provide financial assistance based on principles of equality, voluntariness, and fairness, with the recipient required to provide guarantees [1]. Group 2: Approval Process - Financial assistance must be reviewed by the finance department and approved by the board of directors [3]. - A minimum of two-thirds of the attending directors must agree to the financial assistance proposal, and related directors must abstain from voting [4]. Group 3: Conditions for Financial Assistance - The company cannot provide financial assistance to related parties such as directors, senior management, or controlling shareholders [2]. - Financial assistance must be documented in agreements specifying conditions, amounts, terms, and liabilities for breach [2]. Group 4: Responsibilities and Oversight - The finance department is responsible for assessing the financial health and creditworthiness of the assistance recipient before providing funds [6]. - The internal audit department will supervise the compliance of financial assistance activities [6]. Group 5: Penalties - Violations of the financial assistance regulations that result in losses or negative impacts on the company will lead to economic liability for the responsible individuals, with severe cases potentially referred to judicial authorities [7]. Group 6: Miscellaneous - The management system will be revised and interpreted by the board of directors and will take effect upon approval [8].

Core Points - The document outlines the working rules of the Compensation and Assessment Committee of Hubei Hendi Pharmaceutical Co., Ltd, established to enhance corporate governance and improve operational efficiency [1][2] - The committee is responsible for evaluating the performance of directors and senior management, as well as reviewing and proposing compensation policies [1][3] Group 1: General Provisions - The committee is a specialized body established by the board of directors, responsible for assessing the performance standards of directors and senior management [1][2] - The committee consists of three members, including two independent directors, and is elected by the board [2][3] Group 2: Responsibilities and Duties - The committee is tasked with formulating performance evaluation standards and compensation policies for directors and senior management, and must submit proposals to the board for approval [11][12] - The chairperson of the committee is responsible for convening meetings, signing reports, and representing the committee to the board [13] Group 3: Meeting Procedures - The committee must hold at least one meeting annually, with additional meetings called as necessary [15][16] - A quorum requires the presence of at least two-thirds of the committee members, and decisions are made by a majority vote [16][17] Group 4: Evaluation Process - The evaluation process for directors and senior management includes self-assessments and performance evaluations based on established criteria [23][24] - The committee may invite directors and senior management to attend meetings when necessary [24][25] Group 5: Miscellaneous Provisions - The rules are effective upon approval by the board and will be amended as necessary to comply with relevant laws and regulations [27][28] - The board is responsible for interpreting these rules [29]

General Overview - The document outlines the work guidelines for the General Manager of Hubei Hendi Pharmaceutical Co., Ltd, aiming to improve the company's governance structure in accordance with relevant laws and regulations [1] Chapter 1: General Principles - The guidelines are established based on the Company Law of the People's Republic of China and the company's articles of association [1] Chapter 2: Qualifications and Appointment Procedures - The General Manager must possess extensive knowledge in economics and management, practical experience in enterprise operations, and familiarity with relevant laws and policies [2] - The appointment of the General Manager is proposed by the Chairman and approved by the Board of Directors, while the Vice General Managers and financial officers are nominated by the General Manager and appointed by the Board [2][3] Chapter 3: Powers and Responsibilities - The General Manager is responsible for managing the company's operations, implementing board resolutions, and reporting to the Board [3] - The General Manager must adhere to laws and regulations, execute board decisions, and focus on market analysis and technological advancement [3][4] Chapter 4: Responsibilities of Other Senior Management - The Vice General Manager assists the General Manager and is responsible for specific areas of work [4] - The financial officer manages the company's financial affairs and reports to the General Manager [4] Chapter 5: Work Structure and Procedures - The company will establish functional departments as needed, with proposals for their setup or dissolution submitted by the General Manager to the Board [5] - The General Manager's office meetings are held to discuss significant management decisions, ensuring scientific and rational decision-making [5][6] Chapter 6: Reporting System - The General Manager is required to report regularly to the Board and inform the Chairman of significant operational matters [6][7] - Immediate reporting is required for critical incidents affecting the company's operations or safety [6][7] Chapter 7: Evaluation and Rewards - The Board's remuneration and evaluation committee is responsible for assessing the performance of the General Manager and other senior management [7] - Significant achievements during the term may lead to rewards, while failures may result in penalties or dismissal [7][8] Chapter 8: Supplementary Provisions - The guidelines are subject to interpretation by the Board and must comply with national laws and the company's articles of association [8][9]